Live updates

Advertisement

Full report: New drug for skin cancer

A new drug to treat skin cancer has been given the go-ahead after being successfully trialled in Newcastle.

Erivedge tablets have shown evidence of shrinking tumours that are too big to be operated on.

Doctors at The Northern Centre for Cancer Care say it is a significant step forward in the fight against the most common type of cancer.

Jonny Blair reports.

Experts say new skin cancer drug is a significant step forward

A new drug to treat skin cancer is available after being successfully trialled in our region.

Erivedge tablets can be used to help shrink head and neck tumours, which are too big to be operated on.

Medical experts say it is a significant step forward in the fight against the most common type of cancer.

Jonny Blair reports.

Advertisement

Daily pill for rare skin cancer

From today a once-a-day pill, that was trialled in Newcastle, will be available for patients with a rare form of skin cancer

Patients with advanced basal cell carcinoma who are not suitable for surgery or radiotherapy could benefit from Erivedge.

Following clinical trials at the Northern Centre for Cancer Care in Newcastle it has been shown to shrink tumours.

The advanced form of the disease affects up to 700 people a year in the UK.

  1. National

Charity hopes cancer drug decision will be reversed

Mia Rosenblatt, head of policy and campaigns at Breast Cancer Campaign hopes NICE's decision on pertuzumab can be reversed following the consultation process:

It's disappointing that a drug that has shown real benefit to women with advanced HER-2 positive breast cancer has not received Nice approval.

However this is an interim decision and we hope that appropriate evidence to show its benefit can be provided and an agreement on cost made so that the NHS see this as a cost-effective treatment that could extend lives.

– Mia Rosenblatt, head of policy and campaigns at Breast Cancer Campaign
  1. National

Breast cancer drug 'benefits remain unclear'

The National Institute for Health and Care Excellence (Nice) says it cannot recommend breast cancer drug pertuzumab for widespread use because clinical trial data could not predict how long the drug might extend people's lives for.

NICE has launched a consultation on the use of pertuzumab among breast cancer patients. Credit: Press Association.

The organisation has now launched a consultation to hear the views of charities, patient groups and drug manufacturers.

Nice chief executive Sir Andrew Dillon said: "The appraisal committee couldn't be sure of the benefits of pertuzumab.

"The main clinical trial did not reflect current medical practice in the UK and despite the research data suggesting the treatment could help delay the growth and spread of the disease, the evidence was not robust enough to confirm for how long pertuzumab may actually extend people's lives."

Load more updates